A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
Pfizer
Neonc Technologies, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
TriSalus Life Sciences, Inc.
University of Pennsylvania
Maastricht University Medical Center
TCR2 Therapeutics
Incyte Corporation
Herlev Hospital
Intensity Therapeutics, Inc.
Gritstone bio, Inc.
Gritstone bio, Inc.
Imperial College London
Incyte Corporation
National Cancer Center Hospital East